We are live on ! Find out more
BIAF icon

bioAffinity Technologies
BIAF

13 hedge funds and large institutions have $863K invested in bioAffinity Technologies in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,099% more capital inflows, than outflows

Capital inflows: $402K | Capital outflows: $33.5K

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

30% more funds holding

Funds holding: 10 → 13 (+3)

1.33% more ownership

Funds ownership: 2.09% → 3.43% (+1.3%)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.19%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$235K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$63.4K
3
GSC
Ground Swell Capital
South Carolina
+$53K
4
UBS Group
UBS Group
Switzerland
+$21.8K
5
IFP Advisors
IFP Advisors
Florida
+$11.4K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$33.2K
2
Clear Street
Clear Street
New York
-$202
3
Wells Fargo
Wells Fargo
California
-$91

BIAF Hedge Fund Activity: Q2 2024 in Review

13 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q2 2024, worth a combined $863K — up 78% from $484K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BIAF positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $235K. The largest seller was Renaissance Technologies, cutting an estimated $33.2K.

  • 13 institutional investors held bioAffinity Technologies (BIAF) as of Q2 2024, up from 10 in Q1 2024.
  • Funds reported $863K of bioAffinity Technologies stock for Q2 2024, up 78% quarter-over-quarter.
  • 3 funds opened new bioAffinity Technologies positions in Q2 2024 and 0 closed out, a net change of +3 holders.
  • The largest bioAffinity Technologies buyer in Q2 2024 was Vanguard Group, an estimated $235K added.
  • The largest bioAffinity Technologies seller in Q2 2024 was Renaissance Technologies, an estimated $33.2K sold.

Based on aggregated 13F filings for Q2 2024.